Original articlesThe application of comparative genomic hybridization as an additional tool in the chromosome analysis of acute myeloid leukemia and myelodysplastic syndromes
Introduction
Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)-related AMLs are a very heterogeneous group of hematological diseases that show a diverse spectrum of chromosomal aberrations, molecular abnormalities, and immunophenotypes. Acute myeloid leukemia may be induced by disruption of the normal structure and function of genes that control the balance of proliferation and differentiation in hematopoietic precursors [1].
In patients with AML, about 20–40% of patients never achieve remission following standard induction chemotherapy. Only 30–40% of patients who achieve remission will eventually become long-term survivors despite treatment with intensification chemotherapy, bone marrow transplantation, or both 2, 3. Therefore, it is greatly beneficial to allocate patients to different risk groups to prevent disease relapse and to improve long-term survival rates. Many parameters can influence prognosis, including age, FAB type, clinical variables, especially presentation white cell count, and the expression of certain immunophenotypic surface markers, but appropriate analysis of chromosomal abnormalities is one of the most valuable prognostic indicators in AML. Chromosomal abnormalities have been reported in 50–95% of patients with primary AML in different studies 2, 4, 5. Those AML patients with specific balanced rearrangements such as t(15;17), t(8;21), or inv(16) have a relatively good prognosis. Those AML patients with complex karyotypes, often including several marker chromosomes, especially patients with monosomy 5 or del(5q), monosomy 7, or abnormalities of 3q, have been regarded as a poor prognostic group 2, 4, 6, 7, 8, 9.
Many cases of AML and MDS have structurally altered chromosomes, as a part of a complex karyotype, which cannot be fully identified by cytogenetic analysis alone. Identification of chromosomal regions involved in rearrangements and net gains and losses of chromosomal copy numbers could be of considerable clinical importance. Fluorescence in situ hybridization (FISH) can provide some information but requires the correct selection of specific probes, and only a few chromosomes or chromosomal regions can be examined in a single experiment in the practical routine laboratory setting.
Comparative genomic hybridization (CGH) was developed to proved an adjunct to FISH and to overcome these drawbacks, as there is no requirement for test material metaphase preparations [10]. It allows more rapid comprehensive assessment of chromosomal gains and losses in a tumor genome in order to predict prognosis and to choose appropriate treatment protocols in AML patients with complex karyotypes that include marker chromosomes.
Nineteen cases with AML or MDS transforation were studied by CGH and FISH to obtain any further information, especially in cases with complex karyotypes studied by conventional cytogenetics.
Section snippets
Patients samples
Nineteen AML or AML/MDS transformation bone marrow samples were analyzed. These were samples in which sufficient material remained after cultures had been set up for routine cytogenetic analysis. Karyotyping and CGH were done independently.
Preparation for CGH experiments
Metaphase spreads were prepared according to standard protocols from phytohemagglutinin-stimulated, methotrexate-synchronized peripheral blood lymphocytes from a karyotypically normal male and female. Test DNA from fresh bone marrow samples and control DNA
Conventional karyotyping and CGH results
In 7 of the 19 patients, normal results were observed both by cytogenetics and CGH. Cytogenetic analysis of the remaining cases revealed complex karyotypes with multiple chromosome aberrations in eight cases, and two cases showed a balanced t(15;17); two cases failed to yield a result. The CGH analysis of these two failed cases (cases 8 and 17) showed a normal result in case 8 and showed multiple gains and losses of specific chromosome regions in case 17. Analysis by CGH could not detect any
Discussion
In hematologic malignancies, exact analysis of certain chromosomal rearrangements—such as unbalanced translocations, marker chromosomes, or ring chromosomes—is a critical step in identifying the genes or chromosomes that are crucially related to the pathogenesis of a disease and are important in predicting the prognosis of the patients. The presence of marker chromosomes or complex chromosome aberrations is a major cause of incomplete G-banding analysis.
Several methods are used to investigate
Acknowledgements
We are grateful to Dr. Cumming, Dr. Fitzsimmons, Dr. Parker, Dr. Shahriari, and Dr. Watson for providing patient samples.
References (29)
- et al.
The prognostic significance of chromosomal analysis and immunophenotyping in 117 patients with de novo acute myeloid leukemia
Leuk Res
(1997) - et al.
Long-term survival in acute myelogenous leukemiaa second follow-up of the Fourth International Workshop on Chromosomes in Leukemia
Cancer Genet Cytogenet
(1994) - et al.
The characterization of chromosomal rearrangements by a combined micro-FISH approach in a patient with myelodysplastic syndrome
Cancer Genet Cytogenet
(1995) - et al.
Polymerase chain reaction-based diagnosis of del(5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval
Blood
(1996) - et al.
Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia
Blood
(1995) - et al.
Translocations and deletions of 5q13.1 in myelodysplasia and acute myelogenous leukemiaevidence for a critical locus
Blood
(1996) - et al.
p53 in Haematologic malignancies
Blood
(1994) Molecular pathogenesis and targets for therapy in myelodysplastic syndrome (MDS) and MDS-related leukemias
Curr Opin Oncol
(1998)- et al.
Chromosomal breakpoints and changes in DNA copy number in refractory acute myeloid leukemia
Leukemia
(1997) - et al.
Cytogenetic study of acute myeloid leukemiacomparison of data obtained in 1991–1996 and 1982–1988
Neoplasma
(1998)
Comparative genomic hybridization in the investigation of myeloid leukemia
Genes Chromosom Cancer
Tailoring the treatment of acute myeloid leukemia
Curr Opin Oncol
Additional chromosome abnormalities confer worse prognosis in acute myeloid leukemia
Br J Haematol
The importance of diagnostic cytogenetics on outcome in AMLanalysis of 1,612 patients entered into the MRC AML 10 Trial
Blood
Cited by (32)
Array-based cytogenetic approaches in acute myeloid leukemia: Clinical impact and biological insights
2012, Seminars in OncologyCitation Excerpt :For example, it was recently demonstrated that in AML patients who had received a haploidentical hematopoietic stem cell transplant, relapse was associated with loss of the patient-specific mismatched HLA haplotype due to acquired UPD of chromosome 6p, which allowed the leukemic cells to escape immune surveillance by the donor-derived antileukemic T cells.53 Numerous studies using aCGH, oligonucleotide, and SNP microarrays have uncovered a broad range of cryptic CNAs in cases of AML with normal karyotype, as well as in patients exhibiting balanced rearrangements or chromosomal imbalances, on standard cytogenetic analysis.21,23,24,26–31,33–36,54–56 While the prevalence of the newly identified lesions varied due to differences in the patient populations studied, varying resolution of the experimental platforms used, and improved algorithms for identifying high-confidence CNAs, all of these studies underscore the tremendous genetic diversity of AML in general and clinically or cytogenetically defined AML subtypes.
Cytogenetic and comparative genomic hybridization study of Indian myelodysplastic syndromes
2011, Cancer EpidemiologyCitation Excerpt :The CGH frequently used in solid tumors where preparations of chromosomes are difficult [6]. The CGH study in haematological malignancies even in MDS patients was less frequently reported [7–9]. The DNA copy number changes reported in 40–70% MDS patients using CGH by different research groups [7–9].
Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing
2008, Cancer Genetics and Cytogenetics